tert-butyl 3-(3-fluorophenethylamino)propanoate | 1035229-21-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl 3-(3-fluorophenethylamino)propanoate
• 英文别名: tert-butyl 3-[2-(3-fluorophenyl)ethylamino]propanoate
• CAS: 1035229-21-0
• 化学式: C₁₅H₂₂FNO₂
• mdl: MFCD32642838
• 分子量: 267.344
• InChiKey: KVSHYWKBWVXWEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.533
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-(3-fluorophenethylamino)propanoate 、 氯甲酸苄酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.08h， 生成 tert-butyl 3-((benzyloxycarbonyl)(3-fluorophenethyl)amino)propanoate
  参考文献：
  名称：

  WO2008/75025

  摘要：

  公开号：
• 作为产物：
  描述：

  丙烯酸叔丁酯 、 3-氟苯乙胺 以 乙醇 为溶剂， 反应 48.0h， 以to give the subtitled compound as an oil to (9.6 g)的产率得到tert-butyl 3-(3-fluorophenethylamino)propanoate
  参考文献：
  名称：

  AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES

  摘要：

  本发明提供了公式（I）的化合物，其中k、Ar、R2、R3、R4、R5、R4'、R5'、R6、R7、A、D、m和E如规范中所定义，以及它们的制备方法、含有它们的制药组合物以及它们在治疗中的应用。

  公开号：

  US20100056508A1

文献信息

• AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES
  申请人：Alcaraz Lilian

  公开号：US20100056508A1

  公开（公告）日：2010-03-04

  The present invention provides compounds of formula (I), wherein k, Ar, R 2 , R 3 , R 4 , R 5 , R 4′ , R 5′ , R 6 , R 7 , A, D, m and E are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了公式（I）的化合物，其中k、Ar、R2、R3、R4、R5、R4'、R5'、R6、R7、A、D、m和E如规范中所定义，以及它们的制备方法、含有它们的制药组合物以及它们在治疗中的应用。
• COMBINATION 408
  申请人：Connolly Stephen

  公开号：US20100144606A1

  公开（公告）日：2010-06-10

  The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclohexyl-N 3 -[2-(3-fluorophenyl)ethyl]-N-(2-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-β-alaninamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist; a p38 inhibitor; a PDE inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease (for example chronic obstructive pulmonary disease (COPD) or asthma); to certain salts of N-Cyclohexyl-N 3 -[2-(3-fluorophenyl)ethyl]-N-(2-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-β-alaninamide and to an intermediate useful in the manufacture of this pharmaceutically active substance and salts thereof.

  本发明提供了一种药物产品、试剂盒或组合物，包括第一活性成分，该成分为N-环己基-N3-[2-(3-氟苯基)乙基]-N-(2-[2-(4-羟基-2-氧代-2,3-二氢-1,3-苯并噻唑-7-基)乙基]氨基}乙基)-β-丙氨酰胺或其盐，以及第二活性成分，所述第二活性成分选自：非类固醇糖皮质激素受体（GR受体）激动剂；抗氧化剂；CCR1拮抗剂；趋化因子拮抗剂（不包括CCR1）；皮质类固醇；CRTh2拮抗剂；DP1拮抗剂；组蛋白脱乙酰化酶诱导剂；IKK2抑制剂；COX抑制剂；脂氧合酶抑制剂；白三烯受体拮抗剂；MPO抑制剂；毒蕈碱受体拮抗剂；p38抑制剂；PDE抑制剂；PPARγ激动剂；蛋白酶抑制剂；他汀类药物；血栓素受体拮抗剂；血管扩张剂；或者ENAC阻滞剂（上皮钠通道阻滞剂）。该药物产品、试剂盒或组合物用于治疗呼吸系统疾病（例如慢性阻塞性肺疾病（COPD）或哮喘），以及N-环己基-N3-[2-(3-氟苯基)乙基]-N-(2-[2-(4-羟基-2-氧代-2,3-二氢-1,3-苯并噻唑-7-基)乙基]氨基}乙基)-β-丙氨酰胺的某些盐和用于制造该药物活性物质及其盐的中间体。
• [EN] AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES<br/>[FR] DÉRIVÉS AMINÉS ET LEUR UTILISATION POUR LES MALADIES INDUITES PAR LE RÉCEPTEUR BÊTA-2 ADRÉNERGIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2008075025A1

  公开（公告）日：2008-06-26

  [EN] The present invention provides compounds of formula (I), wherein k, Ar, R², R³, R⁴, R⁵, R^4', R^5', R⁶, R⁷, A, D, m and E are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
  [FR] La présente invention concerne des composés de formule (I), dans laquelle k, Ar, R², R³, R⁴, R⁵, R^4', R^5', R⁶, R⁷, A, D, m et E sont tels que définis dans la spécification, leurs procédés de préparation, des compositions pharmaceutiques qui les contiennent et leur utilisation thérapeutique.
• [EN] PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT UN COMPOSÉ 4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7-YLE POUR LA MODULATION DE L'ACTIVITÉ DES BÊTA-2-ADRÉNORÉCEPTEURS
  申请人：ASTRAZENECA AB

  公开号：WO2009154562A1

  公开（公告）日：2009-12-23

  The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclohexyl-Λ/3-[2-(3-fluorophenyl)ethyl]-Λ/-(2-[2-(4- hydroxy-2-oxo-2,3-dihydro- 1,3-benzothiazol-7-yl)ethyl]amino} ethyl)-β-alaninamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCRl antagonist; a chemokine antagonist (not CCRl); a corticosteroid; a CRTh2 antagonist; a DPI antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist; a p38 inhibitor; a PDE inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease (for example chronic obstructive pulmonary disease (COPD) or asthma); to certain salts of A/-Cyclohexyl-N3-[2-(3-fluorophenyl)ethyl]- N-(2-[2-(4-hydroxy-2-oxo-2,3-dihydro-l,3-benzothiazol-7-yl)ethyl]amino}ethyl)-β- alaninamide and to an intermediate useful in the manufacture of this pharmaceutically active substance and salts thereof.
• [EN] COMBINATION COMPRISING 6-FLU0R0-N- ((1S, 4S) - 4- (6-FLUORO-2, 4-DI0X0-1- (4'- (PIPERAZIN-1- YLMETHYL) BIPHENYL- 3-YL) -1, 2-DIHYDROPYRIDO [2, 3-D] PYRIMIDIN-3 (4H) - YL) CYCLOHEXYL) IMIDAZO [1,2-A] PYRIDINE -2- CARBOXAMIDE OR A SALT<br/>[FR] COMBINAISON COMPRENANT DU 6-FLUORO-N-((1S,4S)-4-(6-FLUORO-2,4-DIOXO-1-(4'-(PIPÉRAZIN-1-YLMÉTHYL)-BIPHÉNYL-3-YL)-1,2-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-3(4H)-YL)CYCLOHEXYL)IMIDAZO[1,2-A]PYRIDINE-2-CARBOXAMIDE OU UN SEL
  申请人：ASTRAZENECA AB

  公开号：WO2010004319A1

  公开（公告）日：2010-01-14

  The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is 6-fluoro-N-((1s,4s)-4-(6-fluoro-2,4-dioxo-1-(4'-(piperazin-1- ylmethy1)-biphenyl-3-yl)-l,2-dihydropyrido[2,3-d]pyrimidin-3(4H)- yl)cyclohexyl)imidazo[l,2-a]pyridine-2-carboxamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a β2 adrenoceptor agonist; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; a MABA compound; an MPO inhibitor; a muscarinic antagonist; a p38 inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.